Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis (Q83081452)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195813%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195813%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

C-B Zhao

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195813%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

X-Q Hu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195813%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J-H Lu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195813%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

C-Z Lu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195813%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

B-G Xiao

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195813%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

X. Zhang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21195813

21 November 2024

H. Zhang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21195813

21 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21195813

21 November 2024

publication date

31 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195813%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

19 January 2020

https://api.elsevier.com/content/article/PII:S1567576910004157?httpAccept=text/xml

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

https://api.elsevier.com/content/article/PII:S1567576910004157?httpAccept=text/plain

21 November 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

International Immunopharmacology

21 November 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195813%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195813%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195813%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

519-524

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195813%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Novel complement inhibitor limits severity of experimentally myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Cytokines and the pathogenesis of myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

The epidemiology of myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Current and future standards in treatment of myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

The mechanism of action of cyclosporin A and FK506

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus).

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Clinical study of fk506 in patients with myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Low-dose tacrolimus for intractable myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Mycophenolate mofetil for myasthenia gravis: an open-label pilot study

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Myasthenia gravis activities of daily living profile

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Multiplexed immunophenotyping of human antigen-presenting cells in whole blood by polychromatic flow cytometry

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Management of severe refractory adult autoimmune enteropathy with infliximab and tacrolimus

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

FK506 prevents induction of rat experimental autoimmune myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study.

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Benefits of FK 506 for refractory eye symptoms in a young child with ocular myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Tacrolimus for myasthenia gravis: a clinical study of 212 patients.

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506.

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Myasthenia gravis appearing after thymectomy: a case report and review of the literature

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Treatment of myasthenia gravis with anti-CD4 antibody: improvement correlates to decreased T-cell autoreactivity

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Cell-surface expression of lymphocyte activation markers in myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

B cell receptor and BAFF receptor signaling regulation of B cell homeostasis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Absence of mature peripheral B cell populations in mice with concomitant defects in B cell receptor and BAFF-R signaling

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Local release of B cell-activating factor of the TNF family after segmental allergen challenge of allergic subjects

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behçet's disease with pulmonary involvement

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.INTIMP.2010.12.012

21 November 2024

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195813%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195813%20AND%20SRC:MED&resulttype=core&format=json